Results 31 to 40 of about 1,816 (199)

Anti‐CD20 therapy for multiple sclerosis‐associated uveitis: A case series

European Journal of Neurology, Volume 29, Issue 10, Page 3028-3038, October 2022., 2022
Approximately 1% of patients with multiple sclerosis (MS) have uveitis, but data on the effects of immunotherapies for MS on MS‐associated uveitis are scarce. In a retrospective study of 12 eyes of six patients with MS‐associated uveitis refractory to previous immunotherapies, we investigated the ophthalmological and neurological outcomes in patients ...
Frauke Stascheit, Anne Rübsam, Carolin Otto, Andreas Meisel, Klemens Ruprecht, Uwe Pleyer   +5 more
wiley   +1 more source

Emerging Theranostic Nanomaterials in Diabetes and Its Complications

Advanced Science, Volume 9, Issue 3, January 25, 2022., 2022
Nanomaterials have been widely used in various areas of medicine due to their mutable structures and extraordinary properties. This review paper comprehensively discusses the recent studies about the mechanisms and applications of functional nanomaterials in diabetes‐related diagnosis, prevention and therapy. Abstract Diabetes mellitus (DM) refers to a
Yuntao Liu, Siqi Zeng, Wei Ji, Huan Yao, Lin Lin, Haiying Cui, Hélder A. Santos, Guoqing Pan   +7 more
wiley   +1 more source

Comparative Efficacy and Safety of Advanced Intravitreal Therapeutic Agents for Noninfectious Uveitis: A Systematic Review and Network Meta-Analysis

Frontiers in Pharmacology, 2022
Background: To compare the efficacy and safety of advanced intravitreal therapeutic regimens, including a dexamethasone implant at 350 and 700 μg; a fluocinolone acetonide (FA) implant, 0.2 µg/day, 0.59 and 2.1 mg; intravitreal bevacizumab, 1.25 mg ...
Weiting Liao, Zhenyu Zhong, Guannan Su, Xiaojie Feng, Peizeng Yang   +4 more
doaj   +1 more source

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review

Journal of Immunology Research, Volume 2021, Issue 1, 2021., 2021
Purpose. To evaluate the effectiveness of Janus kinase (JAK) inhibitors for the treatment of patients with autoimmune disease and associated inflammatory ocular diseases. Methods. We identified relevant literature by screening the MEDLINE, PubMed, and Cochrane databases for randomized controlled trials, cohort studies, case controls, and case reports ...
Ji Wen, Huifang Hu, Menglin Chen, Hang Yang, Yi Zhao, Yi Liu, Chiara Posarelli   +6 more
wiley   +1 more source

Analysis of urgent follow up visits and complications after intravitreal injections: a retrospective cohort study

International Journal of Retina and Vitreous, 2022
Background Intravitreal injections (IVIs), a common treatment in ophthalmology, result in acute complications and urgent follow-up visits causing significant burden to both patient and physician.
Alexander Miller, Matthew A. Wilneff, Andrew Yazji, Emily Petrinec, Michael Carbone, Chase Miller, Christina McCrossin, Richard Donkor, David G. Miller   +8 more
doaj   +1 more source

Intravitreal Therapy for Diabetic Macular Edema: An Update

Journal of Ophthalmology, Volume 2021, Issue 1, 2021., 2021
Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite that DME represents a sight‐threatening condition, it is also among the most accessible to treatment. Many different treatment options including photocoagulation, intravitreal medical treatment (either vascular endothelial growth factor inhibitors or ...
Claudio Furino, Francesco Boscia, Michele Reibaldi, Giovanni Alessio, Enrique Mencía-Gutiérrez   +4 more
wiley   +1 more source

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti‐VEGF

Journal of Ophthalmology, Volume 2021, Issue 1, 2021., 2021
Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti‐VEGF) is the first‐line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns. In pseudophakic eyes with suboptimal response to first‐line therapy, intravitreal corticosteroids may also be used.
Di Zou, Imran Jawaid, Winfried M. Amoaku, Marcel Menke   +3 more
wiley   +1 more source

Corticosteroid implants for chronic non-infectious uveitis. [PDF]

, 2016
BACKGROUND: Uveitis is a term used to describe a heterogeneous group of intraocular inflammatory diseases of the anterior, intermediate, and posterior uveal tract (iris, ciliary body, choroid).
Brady, Christopher J, Garg, Sunir J., Law, Hua Andrew, Rahimy, Ehsan, Reddy, Rahul, Sieving, Pamela C., Tang, Johnny, Villanti, Andrea C   +7 more
core   +2 more sources

Treatment chronic macular edema in Vogt-Koyanagi Harada syndrome with dexamethasone intravitreal implant: description of three case [PDF]

, 2015
Purpose: To report our experience with dexamethasone intravitreal implant (Ozurdex, DEX implant) in the chronic cystic macular edema (ME )with Vogt-Koyanagi-Harada (VKH) Syndrome. Method: A retrospective chart review of three patients with (VKH) treated
Albanese, Giorgio, Campagna, Orazio, Pacella, Elena, Pacella, Fernanda, Smaldone, Gianpaolo, Turchetti, Paolo   +5 more
core   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T., Bonfiglio V., Fallico M., Fichera S., Longo A., Macchi I., Pizzo A., Rapisarda C., Reibaldi M., Russo A.   +9 more
core   +2 more sources